Benefits
Chronic Venous Insufficiency Treatment
Hesperidin combined with diosmin (Daflon®/Detralex®) is established prescription medication in Europe for chronic venous insufficiency (varicose veins, leg edema, leg pain). Multiple meta-analyses and the RELIEF Study (Jantet 2002) confirm efficacy. Substantial evidence base.
Hemorrhoid Treatment
Hesperidin/diosmin is first-line nonsurgical treatment for hemorrhoidal disease in many European guidelines. Reduces bleeding, pain, swelling. Comparable efficacy to many topical/surgical interventions for grade I-II hemorrhoids.
Microcirculation / Capillary Fragility
Reduces capillary fragility and improves microcirculation — relevant for diabetes, retinopathy, easy bruising, lymphedema. Long-established 'venotonic' agent.
Anti-Inflammatory / Antioxidant
Reduces inflammatory markers, oxidative stress, endothelial dysfunction — broad cardiovascular protective effects beyond just venous applications.
Modest Cardiovascular Risk Marker Effects
Some trials show modest improvements in blood pressure, lipids, endothelial function. Effect smaller than dedicated cardiovascular medications. General CV support component.
Mechanism of action
Venotonic / Vasoconstrictor Activity
Hesperidin (and diosmin) increase venous tone and reduce venous distensibility — basis for venous insufficiency treatment. Improves valve function and reduces venous reflux.
Lymphatic Drainage Enhancement
Increases lymphatic contractility — improves lymph drainage. Relevant for edema, lymphedema, lymphatic stagnation.
Anti-Inflammatory / Adhesion Molecule Reduction
Reduces leukocyte adhesion to endothelium, decreases inflammatory cytokines. Limits the inflammatory cascade that contributes to chronic venous disease.
Capillary Permeability Reduction
Decreases capillary permeability — reduces fluid leakage, improves capillary integrity. Foundational mechanism for 'capillary fragility' applications.
Clinical trials
Large prospective international study of micronized purified flavonoid fraction (90% diosmin + 10% hesperidin) in 5,052 patients with chronic venous insufficiency for 6 months.
5,052 CVI patients (international).
Significant improvement in CVI symptoms (edema, pain, leg heaviness, cramps), quality of life. Foundational evidence supporting MPFF as venous insufficiency treatment. Multiple subsequent meta-analyses confirmed efficacy.
Meta-analyses and systematic reviews of MPFF (diosmin/hesperidin) for hemorrhoidal disease.
Pooled across hemorrhoid RCTs.
MPFF significantly reduces hemorrhoid bleeding, pain, swelling. Recommended in European guidelines. Reasonable first-line nonsurgical option.
About this ingredient
Hesperidin (4'-methoxy-7-O-rutinosyl-naringenin) is a FLAVANONE GLYCOSIDE found primarily in CITRUS FRUITS — particularly the WHITE INNER PEEL (pith) and segment membranes of ORANGES, grapefruits, lemons, mandarins. Concentration highest in peel and pith (which are typically discarded) — basis for citrus-derived supplements.
KEY PRODUCT: MICRONIZED PURIFIED FLAVONOID FRACTION (MPFF) — DAFLON® 500 (Servier) / DETRALEX® — contains 450 mg diosmin + 50 mg hesperidin per tablet; PRESCRIPTION drug status in many European countries; OTC supplement in US; most clinically-studied formulation. STRONGER EVIDENCE BASE THAN MOST SUPPLEMENT INGREDIENTS — multiple large RCTs and meta-analyses.
EVIDENCE-BASED USES: (1) CHRONIC VENOUS INSUFFICIENCY — RELIEF Study (Jantet 2002, n=5,052) and others; foundational; (2) HEMORRHOIDAL DISEASE — first-line nonsurgical treatment in European guidelines; (3) Lymphedema, varicose veins; (4) Capillary fragility; (5) Diabetic retinopathy adjunct (microvascular protection); (6) General cardiovascular and microcirculation support.
CRITICAL CAUTIONS: (1) MPFF VS PURE HESPERIDIN — most clinical evidence uses MPFF (diosmin/hesperidin combination); pure hesperidin alone has less direct evidence; products vary significantly; for venous indications, MPFF or equivalent diosmin-hesperidin combinations preferred; (2) PREGNANCY/LACTATION — limited supplemental safety data; CVI in pregnancy is common but consult prescriber; dietary citrus safe; (3) DRUG INTERACTIONS — minimal; theoretical CYP3A4 effects; (4) SOURCING — citrus peel-derived; allergic reactions to citrus theoretical; (5) DOSE — 500-1,000 mg/day general; MPFF 1,000 mg/day for venous indications; (6) DURATION — often used long-term (3-6+ months) for chronic venous disease; safe profile supports this; (7) ADJUNCTIVE TO COMPRESSION — for venous insufficiency, COMPRESSION STOCKINGS remain foundational; hesperidin/diosmin is adjunct; (8) US AVAILABILITY — supplements include hesperidin alone (cheaper but less evidence) or MPFF (more clinically validated); (9) AGAINST hemorrhoids, conservative measures (fiber, hydration, sitz baths) are foundational; MPFF is reasonable nonsurgical option; surgical/procedural intervention for refractory cases; (10) HESPERIDIN BIOAVAILABILITY — modest; micronized forms improve absorption; gut microbiome converts hesperidin to active metabolites; (11) DIETARY SOURCES — orange juice (with pulp), whole oranges, lemon zest provide modest hesperidin; therapeutic doses require supplementation; (12) The strong evidence base for venous indications distinguishes hesperidin/MPFF from many supplement claims with weaker support.